You are here
Home > Oncology > Gemtuzumab Ozogamicin-Mylotarg®

oncology header image

Feel free to use our complete database with charts, tables and examples.

Gemtuzumab Ozogamicin - Mylotarg®

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither NewMedicalTerms Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.    PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

Removed from the U.S. Market on June 2010  (voluntary)
Dilution Data
[Amount of drug] [Infusion volume] [Infusion rate]
Removed from the U.S. Market on June 2010  (voluntary)

Stability / Miscellaneous

Gemtuzumab Ozogamicin-Mylotarg®